Since my last articles on smallpox and anthrax, I found out about Cangene (OTCPK:CGNOF), a Canadian company. Looking into it, I found out that Cangene has products related to smallpox and anthrax. For anthrax, it got an award from the US department of Health and Human Services on July 28, 2006 to purchase 10,000 therapeutic courses of treatment of Anthrax Immune Globulin [AIG] for a total of $143,833,719 (source).
Fascinating that two companies (Cangene and Emergent Biosolutions (NYSE:EBS)) use the same nomenclature for their anthrax antibody – AIG. AIG is not a common acronym such as IVIG (intravenous immunoglobulin) that many companies use. The companies should talk to each other to avoid confusion over which company has the rights to use the term AIG.
Anyway, I found Cangene to be an interesting company. It deals not only with biopharmaceutical products but also is into contract manufacturing. Among the biopharmaceutical products, it has
- WinRho® SDF (Rho(NYSE:D) Immune Globulin) is licensed to treat immune thrombocytopenic purpura [ITP].
- HepaGam B™ [Hepatitis B Immune Globulin Intravenous (Human)] is the first HBIG licensed by the FDA for the prevention of Hepatitis B recurrence following liver transplantation in HBsAg-positive liver transplant patients. HepaGam B is also FDA licensed for treatment of acute exposure to hepatitis B infection.
- VariZIG™ (Varicella Zoster Immune Globulin) is a licensed, highly purified and specialized antibody preparation against the virus that causes chickenpox.
- Vaccinia Immune Globulin [VIG] is Cangene's first biodefense product licensed by the US Food & Drug Administration. VIG contains specific antibodies to the vaccinia virus (the virus used to make smallpox vaccine) and is licensed to treat certain complications associated with smallpox vaccination to the smallpox vaccine.
- Botulism Antitoxin Botulism Antitoxin [BAT] is an investigational product containing neutralizing antibodies to seven botulinum toxin types: A, B, C, D, E, F, and G.
- Leucotropin™ [GM-CSF] is a protein that stimulates the production of infection-fighting white blood cells in the body depleted by chemotherapy and radiation.
- Accretropin™ Cangene's Human Growth Hormone. Accretropin™ has been licensed by the FDA.
It trades on the Toronto exchange as CNJ.TO. The 52wk Range is from $4.75 to $8.51. Presently it trades around $5.